View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
  2. Company News
August 24, 2018updated 12 Jul 2022 1:12pm

AstraZeneca reports negative top-line results from AERISTO trial

AstraZeneca has reported negative top-line results from the AERISTO trial, a Phase IIIb study of Bevespi Aerosphere (glycopyrronium/formoterol fumarate) against umeclidinium/vilanterol for the treatment of patients with moderate to very severe chronic obstructive pulmonary disease (COPD).

AstraZeneca has reported negative top-line results from the AERISTO trial, a Phase IIIb study of Bevespi Aerosphere (glycopyrronium/formoterol fumarate) against umeclidinium/vilanterol for the treatment of patients with moderate to very severe chronic obstructive pulmonary disease (COPD).

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

The results have revealed that Bevespi Aerosphere showed non-inferiority to umeclidinium/vilanterol on peak forced expiratory volume in one second (FEV1), but did not show improvement on peak FEV1 or non-inferiority on trough FEV1.

The trial, however, showed that the safety and tolerability data of Bevespi Aerosphere were consistent with the known profile of the medicine.

Bevespi Aerosphere is a fixed-dose combination of dual bronchodilator combining glycopyrronium, a long-acting muscarinic agonist (LAMA), and a long-acting beta2-agonist (LABA) formoterol fumarate.

AstraZeneca Respiratory and Global Medicines Development head Dr Colin Reisner said: “The efficacy and safety of Bevespi Aerosphere has been established by the Phase III PINNACLE trial programme involving more than 5,000 patients.

“The performance of Bevespi Aerosphere in AERISTO is inconsistent with previous data.”

“The performance of Bevespi Aerosphere in AERISTO is inconsistent with previous data.

“A full analysis is underway to understand and characterise these findings and will be presented at a forthcoming medical meeting.”

The AERISTO included a 24-week, randomised, double-blinded, double-dummy, multicentre, parallel-group trial design.

It evaluated the efficacy and safety of Bevespi Aerosphere in comparison with umeclidinium/vilanterol in 1,119 COPD patients.

During the trial, the patients were randomised to receive either two inhalations twice a day of Bevespi Aerosphere 7.2µg/4.8µg via a pressurised metered-dose inhaler or one inhalation once a day of umeclidinium/vilanterol 62.5µg/25µg via dry powder inhaler.

Primary objectives of the AERISTO were peak change from baseline in FEV1 where non-inferiority and superiority were measured, as well as change from baseline in trough FEV1 where non-inferiority was measured.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena